Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04804930
Recruiting Observational

Trichoscopy and Systemic Scleroderma

NCT04804930 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Lille
Phase
Observational
Started
2021-11-08
Last updated
2026-04-22

Condition(s) studied

Scleroderma, Systemic

Investigational drug(s) / intervention(s)

picture

picture: We will perform a non-invasive assessment of the scalp with a dermoscope by taking two standardized pictures on the frontal area and the occipital area in order to a blinded analysis of trichoscopic patterns

Study summary

* Few data are available on scalp involvement in systemic scleroderma.
* Few data are available on the association between scalp abnormalities and features of systemic scleroderma
* Trichoscopy is a simple, reproducible, noninvasive examination that is part of the examination of hairy areas in routine dermatologic practice
* There is a lack of simple, noninvasive examinations to evaluate patients with systemic scleroderma

The objective will be to evaluate the contribution of trichoscopy in the evaluation of patients with systemic scleroderma

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patient who fulfils the Systemic scleroderma ACR-EULAR 2013 criteria * Signed informed consent * Being social insured Exclusion Criteria: * Patients aged less than 18 years old * patients under legal protection * patients deprived of their liberty * patients in emergency situations * patients who refused or unable to give informed consent * For the control group: sclap inflammatory disease active the day of the examination

Primary outcome measure(s)

  • Frequency of elementary lesions observed by trichoscopic assessment of the scalp — Baseline
    Comparison of the frequencies of elementary lesions visualized in patients with systemic scleroderma and healthy subjects

Trial sites (1)

FacilityCityRegionStatus
Hop Claude Huriez Chu Lille Lille France Recruiting

More University Hospital, Lille trials in France

Intraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation Recruiting
Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations Recruiting
Algorithm-based Management to Reduce the Recurrence of GI Bleeding and Severe Epistaxis in Von Willebrand Disease Recruiting
Lung Disease and FLNA Mutations Starting soon
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma Active, not recruiting

Other trials for the same condition

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Recruiting
Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04804930 on ClinicalTrials.gov ↗ ← All trials in France